Navigation Links
Jazz Pharmaceuticals to Announce Fourth Quarter and Full Year 2009 Financial Results on March 3, 2010
Date:2/23/2010

PALO ALTO, Calif., Feb. 23 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that it will report its fourth quarter and full year 2009 financial results and discuss 2010 financial guidance on Wednesday, March 3, 2010. Jazz Pharmaceuticals will host an investor conference call and live webcast to give a company update, as well as to discuss financial results and guidance, on March 3, 2010, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time.

The live webcast and press release may be accessed from the Investors section of the Jazz Pharmaceu
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... OAKS, Calif. , May 29, 2015 /PRNewswire/ ... pooled data from two pivotal Phase 3, global, ... calcimimetic, for the treatment of secondary hyperparathyroidism (SHPT) ... hemodialysis. Both studies met the primary endpoint, demonstrating ... AMG 416 groups achieved a greater than 30 ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
... (Nasdaq: MYL ) today confirmed that the ... Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation in connection with ... with the U.S. Food and Drug Administration (FDA) for ... 0.05 mg/day, 0.075 mg/day and 0.1 mg/day. This product ...
... would tax the companies that manage prescription drug benefits ... owners they contract with – will drive up prescription ... Management Association (PCMA), the trade group for America,s pharmacy ... of America,s businesses, state and federal government agencies, and ...
Cached Medicine Technology:Mylan Confirms First-to-File Patent Challenge Relating to Vivelle-Dot® 2PCMA: Mississippi's 'Secret Prescription Drug Tax' Will Raise Costs 2
(Date:5/29/2015)... 29, 2015 Intermountain Healthcare ... with Stratus Video Interpreting for ... better communication and timely care for patients ... loss. Stratus’ video remote interpreting (VRI) services ... staff to quickly access qualified medical interpretation ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... 2015 Mediaplanet has joined forces with ... Skin Health is a cross-platform campaign with a ... of New York, Los Angeles, and Chicago, the campaign ... digital counterpart will reach a national audience through one ... the Skin Health campaign and Colorescience, click here ...
(Date:5/29/2015)... OncLive proudly announces the 2015 ... recognized by a panel of eminent oncologists for landmark ... Honorees will be introduced and celebrated TONIGHT at the ... 8:30-11:00 p.m. CDT at The Chicago Illuminating Company, 2110 ... recognized for groundbreaking accomplishments, in fields including translational research, ...
(Date:5/29/2015)... May 29, 2015 Healthpointe is ... with specialists, physical therapy, and injections , For ... back and/or lower back pain, Healthpointe has a ... for herniated discs, disc protrusions and other causes ... , Healthpointe’s team of renowned surgeons are now ...
Breaking Medicine News(10 mins):Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 2Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 3Health News:OncLive's 2015 Giants of Cancer Care™ Awards Announced Today 4Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3
... University of Texas MD Anderson Cancer Center has been awarded ... caused by head and neck cancer radiation treatment, can be ... The $2.7 million grant awarded by the National Cancer ... a perfect score from peer scientists evaluating grant proposals for ...
... Doheny HealthDay Reporter , TUESDAY, March 22 ... for the recommended five years protects women from breast ... drug and it also shields some women from cardiovascular ... heart-disease risk reduction were noted 15 years after starting ...
... 22 (HealthDay News) -- Nurses often don,t speak up ... workers making mistakes that could harm patients, new research ... steps to reduce medical errors through measures such as ... automated medication-dispensing systems. But the study, which included ...
... Jenifer Goodwin HealthDay Reporter , TUESDAY, March 22 ... called fibrates is on the rise in the United States ... improve health, researchers say. Fibrates are often prescribed to ... high levels of triglycerides, a harmful form of fat circulating ...
... work in Lewy body dementia , the Harry T. ... gift, pledged over four years. Lewy body dementia, which combines ... , is the second most common form of dementia in ... and video resources, including excerpts from an interview with Drs. ...
... University has started recruiting patients for a new ... whether the cholesterol-reducing drug rosuvastatin is effective in ... laboratory research and population studies have shown that ... lowers cholesterol, had fewer colon polyps, which can ...
Cached Medicine News:Health News:UT MD Anderson receives grant for study of acupuncture in cancer 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 2Health News:Tamoxifen May Offer Long-Term Heart, Cancer Protection 3Health News:Study: Reluctance to Speak Up Encourages Medical Errors 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 2Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 3Health News:Study Questions Rise in Use of Certain Cholesterol Drugs 4Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 2Health News:Gift will allow Mayo researchers to explore cause of dementia in the elderly 3Health News:Jefferson clinical trial: Can a cholesterol drug prevent colon cancer? 2
... patented Miami J® collar is designed to ... patient. Break-through fabrics inhibit decubitus during long-term ... and speed recovery. And the unique ... any prefabricated extended wear collar. And kids ...
One-piece rigid cervical collar is designed to fit securely around the neck and mandible to provide immobilization and support of the cervical region...
Model C-10 is a four post cervical orthosis which controls flexion, extension, lateral flexion, rotation, and axial motion. Each post may be individually adjusted in height....
... Orthosis ensures comfort and immobilization ... anterior frame and occipital component. ... flow and easy application. Large ... For added comfort, removable, flannel-covered, ...
Medicine Products: